Reference

A thin layer chromatography method to identify oxaliplatin in aqueous solution

A thin layer chromatography method to identify oxaliplatin in aqueous solution. Hernandez-Trejo, Norma; Hampe, Anja; Mueller, Rainer Helmut ( Department of Pharmaceutical Technology, Biotechnology & Quality Management, Free University of Berlin, Berlin, Germany). Pharmazeutische Industrie, 66(12), 1545-1550 (English) 2004 Editio Cantor Verlag. CODEN: PHINAN. ISSN: 0031-711X. DOCUMENT TYPE: Journal CA Section: 64 (Pharmaceutical Analysis) Within the prepn. process of medicines in pharmacies - in addn. to having a recognized anal. certificate - the identity of the drug needs to be confirmed. Ideally this should be done in a non-destructive way that the packaged drug can subsequently still be used for the medicine prepn. To achieve this, a new thin layer chromatog. (TLC) method to identify oxaliplatin (CAS 61825-94-3) was developed. This method can be used during the quality assurance of oxaliplatin prepns. for infusion. The method offers the possibility of directly using an aq. prepn. of oxaliplatin instead of an addnl. sample prepn. involving the weighing of the drug powder. The main advantage when using aq. oxaliplatin solns. is the redn. of the occupational risk for the pharmacist when handling hazardous drugs, and the protection of the sterility of the drug powder soln. before the administration of the prepns. In the present method a Silica 60 F254 aluminum sheet is used as a stationary phase and a quaternary mobile phase consisting of methanol-tetrahydrofuran-triethylamine-water (:0.5:1.25 vol./vol.). After a development of 8 cm in a presatd. chamber, the chromatog. layer is dried, followed by visual inspection under a UV lamp at 254 nm. Oxaliplatin spots can be detected with a retention factor (rf) of ~ 0.7, also after chem. derivatization with specific reagents. The specification of the method is based on the rf comparison of the oxaliplatin spots obtained for a test and a ref. soln. Addnl., if the intensity of the sample spot lies between the color and the intensity of the ref. soln. spot, the drug should be identified as oxaliplatin. The selectivity and the intermediate precision of the method were investigated in this study. The first was achieved by comparing oxaliplatin with potential impurities and ref. substances, described in the current monograph of the European Pharmacopoeia. After the anal. of a test batch of oxaliplatin by 2 different analysts, no significant differences were obsd. after statistical comparison of means and variances.

Antitumor activity of l-OHP in mice

Antitumor activity of l-OHP in mice. Mathe, G.; Kidani, Y.; Noji, M.; Maral, R.; Bourut, C.; Chenu, E. (Inst. Cancerol. Immunogenet., Hop. Paul-Brousse, Villejuif 94804, Fr.). Cancer Lett. (Shannon, Irel.), 27(2), 135-43 (English) 1985. CODEN: CALEDQ. ISSN: 0304-3835. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The title compd. (I) [61825-94-3] was more active against L1210 leukemia and LGC lymphoma in mice than cisplatin; I was equieffective with cisplatin against AkR murine leukemia but showed less toxicity. Both drugs were inactive against solid tumors in mice (Lewis lung carcinoma, MA 16-C mammary carcinoma, glioma 26, and B-16 melanoma). The LD10 and LD50 of I was similar to cisplatin; however, I did not cause renal toxicity.